165 related articles for article (PubMed ID: 19254645)
1. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].
Soler-Palacín P; Fàbrega A; María López R; Figueras C
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645
[No Abstract] [Full Text] [Related]
2. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
[TBL] [Abstract][Full Text] [Related]
3. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
[No Abstract] [Full Text] [Related]
4. Tipranavir.
Gallant J
Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
[No Abstract] [Full Text] [Related]
5. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
6. Aptivus capsules granted full FDA approval.
AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
[No Abstract] [Full Text] [Related]
7. Tipranavir: a ritonavir-boosted protease inhibitor.
Croom KF; Keam SJ
Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
[TBL] [Abstract][Full Text] [Related]
8. New protease inhibitor offers clinicians hope for better salvage therapy.
Murphy MJ
HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
[No Abstract] [Full Text] [Related]
9. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.
Best B; Haubrich R
Expert Opin Investig Drugs; 2006 Jan; 15(1):59-70. PubMed ID: 16370934
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
11. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
[TBL] [Abstract][Full Text] [Related]
12. New black box warning for ritonavir-boosted tipranavir.
Ryan CT
AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
[No Abstract] [Full Text] [Related]
13. Tipranavir: new drug. HIV protease inhibitor. A last resort.
Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
[TBL] [Abstract][Full Text] [Related]
14. Tipranavir.
Plosker GL; Figgitt DP
Drugs; 2003; 63(15):1611-8. PubMed ID: 12887268
[TBL] [Abstract][Full Text] [Related]
15. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
16. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
de Requena DG; Bonora S; Calcagno A; D'Avolio A; Siccardi M; Fontana S; Milia MG; Sciandra M; Garazzino S; Di Garbo A; Baietto L; Trentini L; Di Perri G
Antimicrob Agents Chemother; 2008 Mar; 52(3):1066-71. PubMed ID: 18160524
[TBL] [Abstract][Full Text] [Related]
17. Tipranavir.
Flexner C; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2005 Dec; 4(12):955-6. PubMed ID: 16370086
[No Abstract] [Full Text] [Related]
18. Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Clotet B; Negredo E; Girard PM; Youle M; Neubacher D
J Acquir Immune Defic Syndr; 2007 Aug; 45(4):479-81. PubMed ID: 17622838
[No Abstract] [Full Text] [Related]
19. Anti-HIV agents. Unexpected results from a tipranavir study.
TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
[No Abstract] [Full Text] [Related]
20. FDA notifications. Accelerated approval of tipranavir.
AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
